Urology Doctors in Dunn, NC - Medicare Status, Address, Contact

1 Urology doctors found. Showing 1 - 1

John Michael Seddon, M.D.
Urology
Medicare: Not Enrolled in Medicare
Practice Location: 700 Tilghman Dr, Suite 722, Dunn, NC 28334
Phone: 910-892-1068 Fax: 910-892-4527

News Archive

Elsevier announces special Issue on Fetal Alcohol Spectrum Disorders

Elsevier Inc., the world's leading publisher of scientific, technical and medical information, announced today that Alcohol has published a special year-end double issue on Fetal Alcohol Spectrum Disorders (FASD). It fills an urgent need to bring the widest possible readership current perspectives on using new research methods to improve identification and diagnosis of offspring at risk for FASD and its associated brain damage and behavioral dysfunction.

FDA clears Proteus ingestible sensor

Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.

Penn researchers demonstrate sound-processing deficits in mice brains with mutated dysbindin gene

Recent studies have identified many genes that may put people with schizophrenia at risk for the disease. But, what links genetic differences to changes in altered brain activity in schizophrenia is not clear. Now, three labs at the Perelman School of Medicine at the University of Pennsylvania have come together using electrophysiological, anatomical, and immunohistochemical approaches - along with a unique high-speed imaging technique - to understand how schizophrenia works at the cellular level.

TraCK study says schoolchildren unlikely to transmit SARS-CoV-2

An interesting new preprint research paper posted to the medRxiv* server reports there is little evidence to suggest the rapid transmission of the virus among school children while attending school.

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

Urology Doctors in Dunn, NC Accepting Medicare